Abstract
A growing body of evidence suggests that low molecular weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the medical management of acute coronary syndromes (ACS) including acute myocardial infarction. Several studies support an early invasive as compared to a conservative (non-invasive) approach utilizing percutaneous coronary intervention (PCI) in these patients. During coronary angiography and PCI systemic anticoagulation usually administering UFH should prevent thrombus formation at the catheter equipment and at the site of vessel injury. The widespread use of UFH as the anticoagulant of choice is explained by low costs, easy reversibility and accepted anticoagulant properties. However, the clinical support for the use of UFH in PCI is largely based on retrospective and observational data only. Compared to UFH, LMWH have distinct pharmacological advantages, including ease of administration and usually no need for monitoring. A major drawback of LMWH is the predominant renal clearance which may lead to unpredictable levels of anticoagulation in patients with impaired renal function. Since LMWH constitute an extremely heterogeneous group of drugs each LMWH should be recognized as an individual pharmaceutical compound. Consequently, pharmacodynamic and pharmacokinetic properties of one LMWH must not be extrapolated for other LMWH. A growing body of evidence supports the use of LMWH in ACS, with or without GPIIb / IIIa receptor antagonists, thrombolysis, or PCI. Although in patients undergoing PCI, LMWH have yet not been shown to be superior to UFH they can safely be administered.
Keywords: Low-Molecular Weight Heparins, LMWH, percutaneous coronary intervention (PCI), unfractionated heparin (UFH)
Current Pharmaceutical Design
Title: Low-Molecular Weight Heparins in Percutaneous Coronary Interventions: Current Concepts, Problems, and Perspectives
Volume: 10 Issue: 4
Author(s): Graf J. and Janssens U.
Affiliation:
Keywords: Low-Molecular Weight Heparins, LMWH, percutaneous coronary intervention (PCI), unfractionated heparin (UFH)
Abstract: A growing body of evidence suggests that low molecular weight heparin (LMWH) is at least as effective as unfractionated heparin (UFH) in the medical management of acute coronary syndromes (ACS) including acute myocardial infarction. Several studies support an early invasive as compared to a conservative (non-invasive) approach utilizing percutaneous coronary intervention (PCI) in these patients. During coronary angiography and PCI systemic anticoagulation usually administering UFH should prevent thrombus formation at the catheter equipment and at the site of vessel injury. The widespread use of UFH as the anticoagulant of choice is explained by low costs, easy reversibility and accepted anticoagulant properties. However, the clinical support for the use of UFH in PCI is largely based on retrospective and observational data only. Compared to UFH, LMWH have distinct pharmacological advantages, including ease of administration and usually no need for monitoring. A major drawback of LMWH is the predominant renal clearance which may lead to unpredictable levels of anticoagulation in patients with impaired renal function. Since LMWH constitute an extremely heterogeneous group of drugs each LMWH should be recognized as an individual pharmaceutical compound. Consequently, pharmacodynamic and pharmacokinetic properties of one LMWH must not be extrapolated for other LMWH. A growing body of evidence supports the use of LMWH in ACS, with or without GPIIb / IIIa receptor antagonists, thrombolysis, or PCI. Although in patients undergoing PCI, LMWH have yet not been shown to be superior to UFH they can safely be administered.
Export Options
About this article
Cite this article as:
Graf J. and Janssens U. , Low-Molecular Weight Heparins in Percutaneous Coronary Interventions: Current Concepts, Problems, and Perspectives, Current Pharmaceutical Design 2004; 10 (4) . https://dx.doi.org/10.2174/1381612043453342
DOI https://dx.doi.org/10.2174/1381612043453342 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploiting Anti-Inflammation Effects of Flavonoids in Chronic Inflammatory Diseases
Current Pharmaceutical Design Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells
Current Pharmaceutical Biotechnology Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design COXIBs, CINODs and H2S-Releasing NSAIDs: Current Perspectives in the Development of Safer Non Steroidal Anti-Inflammatory Drugs
Current Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Meet Our Co-Editor
Cardiovascular & Hematological Agents in Medicinal Chemistry Personalizing Stem Cell Research and Therapy: The Arduous Road Ahead or Missed Opportunity?
Current Pharmacogenomics and Personalized Medicine Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies
Central Nervous System Agents in Medicinal Chemistry Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Regulation of Cardiac Nerves: A New Paradigm in The Management of Sudden Cardiac Death?
Current Medicinal Chemistry Application of Stem Cells in Cardiology: Where we are and where we are Going
Current Stem Cell Research & Therapy Synthesis of Novel Benzoquinones with Anti-Inflammatory Activity
Letters in Drug Design & Discovery Endotoxin, TLR4 Signaling and Vascular Inflammation: Potential Therapeutic Targets in Cardiovascular Disease
Current Pharmaceutical Design Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Conference Report: 10th International Summer School of Neurology: Celebrating a Decade of Success: 5th July, 2015 – 9th July, 2015 | Eforie Nord, Romania
CNS & Neurological Disorders - Drug Targets 30 Years Lost in Anesthesia Theory
Cardiovascular & Hematological Agents in Medicinal Chemistry Detection of Myocardial Ischemia in Patients with Blunted Hemodynamic Response to Adenosine Stress
Current Medical Imaging Benefits of L-Arginine on Cardiovascular System
Mini-Reviews in Medicinal Chemistry